Cost, Value and Access of Personalized Medicine

Linda D. Bosserman, MD, FACP

Video Categories: Value

Linda Bosserman provides an overview of the nuances of personalized medicine as it relates to cost, value and access
March 31, 2015

Reality of the ASPIRE Study

Ajai Chari, MD, at the Mount Sinai School of Medicine in New York, deliberates on the results of the ASPIRE study as the most important thing to come out of ASH for the myeloma community. He mentions that although the study has very positive indications, the therapy isn’t really appropriate [ Read More ]

March 31, 2015

Beginnings of Personalized Medicine for Myeloma

Dr. Ajai Chari talks about risk-based treatment for myeloma as the beginning of personalized medicine in the field. The 2 most recent advances are the increased use of proteasome inhibitors for those with the 4;14 translocation and treating those identified with high molecular risk more aggressively.